Review: Pharmacokinetics and pharmacodynamics of the taxanes

Journal of Oncology Pharmacy Practice

Volumn 3, Issue 2, 1997, Pages 76-93

  Lam, Francis Y W ^a,b   Chan, Jennifer C Y ^a,b   Kuhn, John G ^a,b  

^a The University of Texas Health Science Center at San Antonio   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Docetaxel; Paclitaxel; Pharmaco dynamics; Pharmacokinetics

Indexed keywords

EID: 0002393030     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/107815529700300202     Document Type: Review

References (114)

1. Piccart MJ Taxoid compounds in breast cancer: Current status and future prospects. In Muggia FM, ed. Concepts, Mechanisms, and New Targets for Chemotherapy. Boston, Mass: Kluwer Academic Publishers; 1995:185-207.
2. Ringel I., Horwitz SB Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst. 1991;83:288-291.
3. Parness J., Kingston DGI, Powell RG, Harracksingh C., Horwitz SB Structure-activity study of cytoxicity and microtubule assembly in vitro by taxol and related taxanes. Biochem Biophys Res Commun. 1982;105:1082-1089.
4. Kingston DGI. The chemistry of taxol. Pharmacol Ther. 1991;52: 1-34.
5. Weiss RB, Donehower RC, Wiernik PH,et al.Hypersensitivity reactions from Taxol. J Clin Oncol. 1990;8:1263-1268.
6. McNeil C. Semisynthetic taxol goes on market amid ongoing quest for new versions. J Natl Cancer Inst. 1995;87:1106-1108.
7. Nicolaou KC, Yang Z., Liu JJ,et al.Total synthesis of taxol. Nature. 1994;367:630 - 634.
8. Greenwald RB, Gilbert CW, Pendri A., Conover CD, Xia J., Martinez A. Drug delivery systems: Water soluble taxol 2'-poly(ethyleneglycol) ester prodrugs-design and in vivo effectiveness. J Med Chem. 1996;39:424 - 431.
9. Mamber SW, Mikkilineni AB, Pack EJ,et al.Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase. J Pharmacol Exp Ther. 1995;274:877-883.
10. Nicolaou KC, Riemer C., Kerr MA, Rideout D., Wrasidlo W. Design, synthesis and biological activity of protaxols. Nature. 1993;364: 464-466.
11. Straubinger RM, Sharma A., Murray M., Mayhew E. Novel Taxol-formulations: Taxol-containing liposomes. Monographs-Nat Cancer Institute. 1993;15:69-78.
12. Schiff P., Fant J., Horwitz S. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665-667.
13. Rowinsky E., Cazenave L., Donehower R. Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82:1247-1259.
14. Diaz JF, Andreu JM Assembly of purified GDP-tubulin into micro-tubules induced by Taxol and Taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry. 1993;32:2747-2755.
15. Gueritte-Voegelein F., Guenard D., Lavelle F., Le Goff MT, Mangatal L., Potier P. Relationship between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991;34:992-998.
16. Roy SN, Horwitz SB A phosphoglycoprotein with Taxol resistance in J774.2 cells. Cancer Res. 1985;45:3856-3863.
17. Schibler MJ, Cabral E. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in α and β-tubulin. J Cell Biol. 1986;102:1522-1531.
18. Holmes FA, Walters RS, Theriault RL,et al.Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83:1797-1805.
19. Hanauske AR, Degen D., Hilsensbeck SG, Bissery MC, Von Hoff DD. Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs. 1992;3:121-124.
20. Seidman AD, Hochhauser D., Gollub M.,et al.Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996;14:1877-1884.
21. Valero V. Treatment of patients resistant to paclitaxel therapy. Anticancer Drugs. 1996;7(Suppl 2):17-19.
22. Pazdur R., Newman RA, Newman BM,et al.Phase I trial of taxotere: Five-day schedule. J Natl Cancer Inst. 1992;84:1781-1788.
23. Burris HA, Irvin R., Kuhn J.,et al.Phase I clinical trial of Taxotere given as either a 2-hour or 6-hour infusion. J Clin Oncol. 1993;11: 950-958.
24. Extra JM, Rousseau F., Bruno R., Clavel M., Le Bail N., Marty M. Phase I and pharmacokinetic study of Taxotere (RP56976 NSC 628503) given as a short intravenous infusion. Cancer Res. 1993;53:1037-1042.
25. Aapro MS, Zulian G., Alberto P., Bruno R., Oulid-Aissa D., Le Bail N. Phase I and pharmacokinetic study of RP56976 in a new ethanol-free formulation of taxotere. Ann Oncol. 1992;3(suppl 5):53.
26. Bissett D., Setanoians A., Cassidy J.,et al.Phase I and pharmacokinetic study of Taxotere (R56976) administered as a 24-hour infusion. Cancer Res. 1993;53:523-527.
27. Bruno R., Vivier N., Vergniol JC, De Phillips SL, Montay G., Sheiner LB A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation. J Pharmacokinet Biopharmaceut. 1996;24:153-172.
28. Launay-Iliadis MC, Bruno R., Cosson V.,et al.Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol. 1995;37:47-54.
29. Bruno R., Dorr MB, Montay G.,et al.Design and prospective implementation of population pharmacokinetic studies during the development of docetaxel (RP 56976), a new anticancer drug. Clin Pharmacol Ther. 1994;55:161.
30. Bruno R., Cosson V., Vergniol JC,et al.Taxotere population pharmacokinetics. Proc Am Assoc Cancer Res. 1993;34:234.
31. Bruno R., Hille D., Thomas L., Riva A., Sheiner LB Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere) in phase II studies. Proc Am Soc Clin Oncol. 1995;14: 457.
32. Bissery MC, Renard A., Montay G., Bayssas M., Lavelle F. Taxotere antitumor activity and pharmacokinetics in mice. Proc Am Assoc Cancer Res. 1991;32:401.
33. Marlard M., Gaillard C., Sanderink G., Roberts S., Joannou P., Facchini V. Kinetics, distribution, metabolism, and excretion of radiolabelled taxotere in mice and dogs. Proc Am Assoc Cancer Res. 1993;34:393.
34. de Valeriola D., Brassinne C., Gaillard C.,et al.Study of excretion balance, metabolism, and protein binding of 14C radiolabelled Taxotere (RP56976, NSC 628503) in cancer patients. Proc Am Assoc Cancer Res. 1993;34:373.
35. Urien S., Barre J., Morin C., Paccaly A., Montay G., Tillement JP Docetaxel serum protein binding with high affinity to alpha-1-acid glycoprotein. Invest Cancer Drugs. 1996;14:147-151.
36. Abramson FP Methadone plasma protein binding: Alterations in cancer and displacement from alpha1-acid glycoprotein. Clin Pharmacol Ther. 1982;32:652-658.
37. Urien S., Albengres E., Pinquier JL, Tillement JP Role of alpha1-acid glycoprotein, albumin and nonesterified fatty acids in serum binding of apazone and warfarin. Clin Pharmacol Ther. 1986;39: 683-689.
38. Royer I., Monsarrat B., Sonnier M., Wright M., Cresteil T. Metabolism of docetaxel by human cytochrome P450: Interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 1996;56:58 - 65.
39. Marre F., Sanderink G., de Sousa G., Gaillard C., Martinet M., Rahmani R. Hepatic biotransformation of docetaxel (Taxotere®) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res. 1996;56:1296 - 1302.
40. Lam YWF, Rizzo JD Taxotere and taxol metabolism by human cytochrome P450 enzymes. Pharmacotherapy. 1996;16:522.
41. Commercon A., Bourzat JD, Bezard D., Vuilhorgne M. Partial synthesis of major human metabolites of docetaxel. Tetrahedron. 1994;50:10289-10298.
42. Hudis CA, Seidman AD, Crown JPA,et al.Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:58-65.
43. Blaney S., Seibel N., O'Brien M.,et al.A phase I study of taxotere in pediatric patients. Proc Am Assoc Cancer Res. 1994;35:211.
44. Wiley TA, Bekos EJ, Gaver RC,et al.High performance liquid chromatographic procedure for the quantitative determination of Taxol (paclitaxel) in human plasma. J Chromatogr. 1993;621:231- 238.
45. Huizing MT, Keung ACF, Rosing H.,et al.Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993;11:2127-2135.
46. Grochow LB, Baraldi C., Noe D. Is dose normalization to weight or body surface area useful in adults. J Natl Cancer Inst. 1990;82: 323-325.
47. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 1994;1:532-538.
48. Wilson WH, Berg SL, Bryant G.,et al.Paclitaxel in doxorubicin-refractory or mitoxanthrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol. 1994;12:1621-1629.
49. Markman MM, Rowinsky E., Hakes T.,et al.Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study. J Clin Oncol. 1992;10:1485-1491.
50. Markman M., Francis P., Rowinsky E.,et al.Intraperitoneal Taxol (Paclitaxel) in the management of ovarian cancer. Ann Oncol. 1994;5(Suppl 6):55-58.
51. Brown T., Havlin K., Weiss G.,et al.A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol. 1991;9:1261-1267.
52. Grem JL, Tutsch KD, Simon KJ,et al.Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep. 1987;71:1179-1184.
53. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987;47:2486-2493.
54. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 1989;49:4640-4647.
55. Rowinsky EK, Gilbert MR, McGuire WP,et al.Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol. 1991;9:1692-1703.
56. Keung ACF, Kaul S., Pinedo HM, Ten Bokkel Huinink WW, Beijnen JH Pharmacokinetics of Taxol given by 3-hr or 24-hr infusion to patients with ovarian carcinoma. Proc Am Soc Clin Oncol. 1993;12:130.
57. Tamura T., Sasaki Y., Eguchi K.,et al.Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. Jpn J Cancer Res. 1994;85:1057-1062.
58. Horikoshi N., Ogawa M., Inoue K.,et al.Pharmacokinetics of a 24-hour infusion of Taxol. Proc Am Soc Clin Oncol. 1993;12:146.
59. Wiernik P., Schwartz E., Einzig A., Strauman JJ, Lipton RB, Dutcher JP Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol. 1987;5:1232-1239.
60. Tamura T., Sasaki Y., Nishiwaki Y., Saijo N. Phase I study of paclitaxel by three-hour infusion: Hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res. 1995;86:1203-1209.
61. Gianni L., Kearns CM, Giani A.,et al.Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol. 1995;13:180-190.
62. Stemmer SM, Cagnoni PJ, Shpall EJ,et al.High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: A phase I trial. J Clin Oncol. 1996;14: 1463-1472.
63. Sparreboom A., van Tellingen O., Nooijen WJ, Beijnen JH Nonlinear pharmacokinetics of paclitaxel in mice resulting from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996;56:2112-2115.
64. Arbuck SG Paclitaxel: What schedule? What dose? J Clin Oncol. 1994;12:233-236.
65. Heimans JJ, Vermorken JB, Wolbers JG,et al.Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol. 1994;5:951-953.
66. Glantz MJ, Choy H., Kearns CM,et al.Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst. 1995;87:1077-1081.
67. Longnecker SM, Donehower RC, Cates AE,et al.High-performance liquid chromatographic assay for Taxol (NSC125973) in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep. 1987;71:53-59.
68. Kumar GN, Walle UK, Bhalla KN, Walle T. Binding of taxol to human plasma, albumin, and α1-acid glycoprotein. Res Commun Chem Pathol Pharmacol. 1993;80:337-344.
69. Huizing MT, Vermorken JB, Rosing H.,et al.Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial. Ann Oncol. 1995;6:699-704.
70. Rahman A., Korzekwa KR, Grogan J., Gonzalez FJ, Harris JW Selective biotransformation of taxol to 6α-hydroxy-taxol by human cytochrome P450 2C8. Cancer Res. 1994;54:5543-5546.
71. Cresteil T., Monsarrat B., Alvinerie P., Treluyer JM, Vieira I., Wright M. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isoenzymes involved in its biotransformation. Cancer Res. 1994;54:386-392.
72. Harris JW, Rahman A., Kim BR, Guengerich FP, Collins JM Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 1994;54:4026-4035.
73. Monsarrat B., Alvinerie P., Wright M.,et al.Hepatic metabolism and biliary excretion of Taxol in rats and humans. Monogr Natl Cancer Inst. 1993;15:39 - 46.
74. Harris JW, Katki A., Anderson LW, Chmurny GN, Paukstelis JV, Collins JM Isolation, structural determination, and biological activity of 6-α-hydroxytaxol, the principal human metabolite of taxol. J Med Chem. 1994;37:706 - 709.
75. Sonnichsen DS, Liu Q., Schietz EG, Schuetz JD, Pappo A., Relling MV Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther. 1995;275:566-575.
76. Hurwitz CA, Relling MV, Weitman SD,et al.Phase I trial of paclitaxel in children with refractory solid tumors: A Pediatric Oncology Group Study. J Clin Oncol. 1993;11:2324-2329.
77. Francis P., Bruno R., Seidman A.,et al.Pharmacodynamics of docetaxel (Taxotere) in patients with liver metastases. Proc Am Soc Clin Oncol. 1994;13:138.
78. Oulid-Aissa D., Bruno R., Lebecq A., Zukiwski A., Sheiner L., Riva A. Taxotere safety in patients with impaired liver function. Proc Am Soc Clin Oncol. 1996;15:476.
79. Rhone Poulenc Rorer Pharmaceuticals, Inc. Docetaxel package insert. Collegevile, Penn, 1996.
80. Gan Y., Wientjes MG, Schuller DE, Au JLS Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 1996;56:2086-2093.
81. Huizing MT, Giaccone G., van Warmerdam LJC,et al.Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol. 1997;15:317-329.
82. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD,et al.European-Canadian randomized trial of taxol in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654-2666.
83. Swenerton K., Eisenhauer E., Ten Bokkel Huinink W.,et al.Taxol in relapsed ovarian cancer: High vs. low dose and short vs. long infusion. Proc Am Soc Clin Oncol. 1993;12:256.
84. Spriggs DR, Tondini C. Taxol administered as a 120 hour infusion. Invest New Drugs. 1992;10:275-278.
85. Vermorken JB, Ten Bokkel Huinink WW, Mandjes IA,et al.High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: A European Cancer Center trial. Semin Oncol. 1995;22: 16-22.
86. Rowinsky EK, Chaudhry V., Forastiere AA,et al.Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993;11:2010-2020.
87. Fisherman JS, Cowan KH, Noone M.,et al.Phase I/II study of 72-hour infusion paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol. 1996;14:774-782.
88. Webster LK, Cosson EJ, Stokes KH, Millward MJ Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer. 1996;73: 522-524.
89. Holmes FA, Madden T., Newman RA,et al.Schedule-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996;14:2713-2721.
90. Schellens JHM, Ma J., Bruno R.,et al.Pharmacokinetics of cisplatin and Taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence taxotere/cisplatin and cisplatin/taxotere in a phase I/II study in solid tumor patients. Proc Am Soc Clin Oncol. 1994;13:132.
91. Ma J., Verweij J., Planting AST,et al.Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leucocytes. Cancer Chemother Pharmacol. 1996;37: 382-384.
92. LeBlanc GA, Sundseth SS, Weber GF, Waxman DJ Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res. 1992;52:540-547.
93. Rowinsky EK, Citardi MJ, Noe DA, Donehower RC Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol. 1993;119:727-733.
94. Calvert AH, Boddy A., Bailey NP,et al.Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol. 1995;22(5, Suppl 12):91-98.
95. Kearns CM, Belani CP, Erkmen K.,et al.Pharmacokinetics of paclitaxel and carboplatin in combination. Semin Oncol. 1995;22(5, Suppl 12):1-4.
96. Reed E., Sarosy G., James-Dow C.,et al.Cimetidine does not influence taxol-steady state plasma levels. Proc Am Assoc Cancer Res. 1993;34:395.
97. Slichenmyer WJ, Donehower R., Chen TL, Bowling MK, McGuire WP, Rowinsky EK Pretreatment H2 receptor antagonists that differ in P450 modulation activity: Comparative effects on paclitaxel clearance rates and neutropenia. Cancer Chemother Pharmacol. 1995;36:227-232.
98. Muller C., Goubin F., Ferrandis E.,et al.Evidence for transcriptional control of human mdr gene expression by verapamil in multi-drug resistant leukemic cells. Mol Pharmacol. 1995;47:51-56.
99. Muller C., Baily JD, Goubin F.,et al.Verapamil decreases P-glycoprotein expression in multidrug resistant human leukemic cell lines. Int J Cancer. 1994;56:749-754.
100. Bhalla K., Huang Y., Tang C.,et al.Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia. 1994;8:465-475.
101. Tolcher AW, Cowan KH, Solomon D.,et al.Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol. 1996;14:1173-1184.
102. Berg SL, Tolcher A., O'Shaughnessy JA,et al.Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol. 1995;13:2039-2042.
103. Tomiak E., Piccart MJ, Kerger J.,et al.Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994;12:1458-1467.
104. Fumoleau P., Chevallier B., Dieras V.,et al.Safety evaluation of two doses of Taxotere (docetaxel) without routine premedication as first line in advance breast cancer (ABC)-EORTC Clinical Screening Group (CSG) report. Proc Am Soc Clin Oncol. 1994;13:109.
105. Ten Bokkel Huinink WW, Prove AM, Piccart M.,et al.A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol. 1994;5:527-532.
106. Chevallier G., Fumoleau P., Kerbrat P.,et al.Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 1995;13:314-322.
107. Schrijvers D., Wanders J., Dirix L.,et al.Coping with toxicities of docetaxel (Taxotere). Ann Oncol. 1993;4:610-611.
108. Vukelja SJ, Baker WJ, Burris HA III. Pyridoxine therapy for palmar-planar erythrodysesthesia associated with taxotere. J Natl Cancer Inst. 1993;85:1432-1433.
109. New PZ, Jackson CE, Rinaldi D., Burris H., Barohn RJ Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology. 1996;46:108-111.
110. Hilkens PH, Verweij J., Stoter G., Vecht CJ, Van Den Bent MJ Peripheral neurotoxicity induced by docetaxel. Neurology. 1996;46:104 - 108.
111. Webster LK, Crinis NA, Morton CG, Millward J. Plasma alcohol concentrations in patients following paclitaxel infusion. Cancer Chemother Pharmacol. 1996;37:499-501.
112. Hobbs WR, Rall TW, Verdoorn TA Hypnotics and sedatives; ethanol. In Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics, 9th ed. New York: Pergamon Press; 1996:361-396.
113. Waugh WN, Trissel LA, Stella VJ Stability, compatibility, and plasticizer extraction of taxol (NSC 125973) injection in infusion solutions and stored in various containers. Am J Hosp Pharm. 1991;48:1520-1524.
114. Pearson SD, Trissel LA Investigation of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm. 1993;50:1405-1409.